Literature DB >> 10964781

Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.

Z Q Beck1, L Hervio, P E Dawson, J H Elder, E L Madison.   

Abstract

The recognition sequences for substrate cleavage by aspartic protease of HIV-1 are diverse and cleavage specificities are controlled by complex interactions between at least six amino acids around the cleavage site. We have identified 45 efficiently cleaved peptide substrates of HIV-1 protease (PR) using substrate phage display, an approach that can elucidate both context-dependent and context-independent preferences at individual subsites of a protease substrate. Many of the selected peptides were cleaved more efficiently and had lower K(m) values than physiologically relevant substrates of HIV-1 PR. Therefore, mutations occurring in the cleavage sites of the Gag and Gag-pol polyproteins of HIV-1 could significantly lower the K(m) values to better compete against drugs for protease binding while maintaining cleavage rates necessary for viral replication. The most efficiently cleaved peptide substrate derived from these phage, Ac-GSGIF*LETSL-NH(2), was cleaved 60 times more efficiently and had a K(m) approximately 260 times lower than a nine-amino-acid peptide based on the natural reverse transcriptase/integrase cleavage site when assayed at pH 5.6, 0.2 M NaCl. The peptide substrates selected served as frameworks for synthesis of tight binding reduced amide inhibitors of HIV-1 PR. The results show that the most efficiently cleaved substrates serve as the best templates for synthesis of the tightest binding inhibitors. Thus, defining changes in substrate preferences for drug-resistant proteases may aid in the development of more efficacious inhibitors. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964781     DOI: 10.1006/viro.2000.0420

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

Authors:  B Bühler; Y C Lin; G Morris; A J Olson; C H Wong; D D Richman; J H Elder; B E Torbett
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Peptide mimotopes of phomopsins: identification, characterization and application in an immunoassay.

Authors:  Meng Yu; Khin Than; Steve Colegate; Brian Shiell; Wojtek P Michalski; Stephen Prowse; Lin-Fa Wang
Journal:  Mol Divers       Date:  2005       Impact factor: 2.943

4.  Predicting human immunodeficiency virus protease cleavage sites in nonlinear projection space.

Authors:  Xuehua Li; Hongli Hu; Lan Shu
Journal:  Mol Cell Biochem       Date:  2010-01-07       Impact factor: 3.396

5.  Engineering an artificial zymogen by alternate frame protein folding.

Authors:  Diana M Mitrea; Lee S Parsons; Stewart N Loh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

6.  A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease.

Authors:  Ian W Windsor; Ronald T Raines
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-06-27       Impact factor: 7.652

7.  Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.

Authors:  Liwen You; Daniel Garwicz; Thorsteinn Rögnvaldsson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.

Authors:  Z Q Beck; Y C Lin; J H Elder
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.

Authors:  Ying-Chuan Lin; Zachary Beck; Garrett M Morris; Arthur J Olson; John H Elder
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Sub-picomolar Inhibition of HIV-1 Protease with a Boronic Acid.

Authors:  Ian W Windsor; Michael J Palte; John C Lukesh; Brian Gold; Katrina T Forest; Ronald T Raines
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.